Targeted therapies in T-cell malignancies View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2006-11-22

AUTHORS

Anskar Y. H. Leung, Raymond Liang

ABSTRACT

The World Health Organization (WHO) has classified T-cell malignancies into mature T-cell and natural killer (NK)-cell neoplasms and precursor T-cell lymphoblastic lymphoma/leukemia. Mature T-cell lymphomas, alternatively known as peripheral T-cell lymphomas (PTCLs), are rare diseases with extremely heterogeneous clinicopathologic profiles. Treatment protocols for PTCL are mostly adapted from those used for B-cell lymphomas, but the prognosis is generally worse. More recently, monoclonal antibodies, including alemtuzumab (Campath-1H, anti-CD52) and denileukin diftitox (Ontak, anti-CD25), have been shown to be effective in the treatment of T-prolymphocytic leukemia (T-PLL) and cutaneous T-cell lymphoma. The unique association of human T-cell lymphotropic virus in adult T-cell lymphoma/leukemia has also led to the use of anti-viral agents in this disease with significant improvement in outcome. A number of novel monoclonal antibodies and histone deacetylase inhibitors are also being evaluated. The roles of these targeted therapies as first-line treatment or in combination with conventional chemotherapy and the roles of autologous and allogeneic hematopoietic stem cell transplantation in PTCL need further investigation. More... »

PAGES

39-47

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11523-006-0035-0

DOI

http://dx.doi.org/10.1007/s11523-006-0035-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1040146758


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Hematology and Bone Marrow Transplantation, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, People\u2019s Republic of China", 
          "id": "http://www.grid.ac/institutes/grid.194645.b", 
          "name": [
            "Division of Hematology and Bone Marrow Transplantation, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, People\u2019s Republic of China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Leung", 
        "givenName": "Anskar Y. H.", 
        "id": "sg:person.011121156664.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011121156664.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Queen Mary Hospital, Department of Medicine, K417, K Block, University of Hong Kong, Pok Fu Lam Road, Hong Kong SAR, People\u2019s Republic of China", 
          "id": "http://www.grid.ac/institutes/grid.194645.b", 
          "name": [
            "Division of Hematology and Bone Marrow Transplantation, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, People\u2019s Republic of China", 
            "Queen Mary Hospital, Department of Medicine, K417, K Block, University of Hong Kong, Pok Fu Lam Road, Hong Kong SAR, People\u2019s Republic of China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liang", 
        "givenName": "Raymond", 
        "id": "sg:person.07707430152.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07707430152.30"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11912-002-0038-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015532547", 
          "https://doi.org/10.1007/s11912-002-0038-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2403955", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010474068", 
          "https://doi.org/10.1038/sj.leu.2403955"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2404306", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020476651", 
          "https://doi.org/10.1038/sj.leu.2404306"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1385/mo:22:2:191", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007072512", 
          "https://doi.org/10.1385/mo:22:2:191"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nbt0698-535", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003509924", 
          "https://doi.org/10.1038/nbt0698-535"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.thj.6200195", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056649458", 
          "https://doi.org/10.1038/sj.thj.6200195"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/332323a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016704652", 
          "https://doi.org/10.1038/332323a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bmt.1702867", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020320997", 
          "https://doi.org/10.1038/sj.bmt.1702867"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2006-11-22", 
    "datePublishedReg": "2006-11-22", 
    "description": "The World Health Organization (WHO) has classified T-cell malignancies into mature T-cell and natural killer (NK)-cell neoplasms and precursor T-cell lymphoblastic lymphoma/leukemia. Mature T-cell lymphomas, alternatively known as peripheral T-cell lymphomas (PTCLs), are rare diseases with extremely heterogeneous clinicopathologic profiles. Treatment protocols for PTCL are mostly adapted from those used for B-cell lymphomas, but the prognosis is generally worse. More recently, monoclonal antibodies, including alemtuzumab (Campath-1H, anti-CD52) and denileukin diftitox (Ontak, anti-CD25), have been shown to be effective in the treatment of T-prolymphocytic leukemia (T-PLL) and cutaneous T-cell lymphoma. The unique association of human T-cell lymphotropic virus in adult T-cell lymphoma/leukemia has also led to the use of anti-viral agents in this disease with significant improvement in outcome. A number of novel monoclonal antibodies and histone deacetylase inhibitors are also being evaluated. The roles of these targeted therapies as first-line treatment or in combination with conventional chemotherapy and the roles of autologous and allogeneic hematopoietic stem cell transplantation in PTCL need further investigation.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11523-006-0035-0", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1036678", 
        "issn": [
          "1776-2596", 
          "1776-260X"
        ], 
        "name": "Targeted Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "2"
      }
    ], 
    "keywords": [
      "peripheral T-cell lymphoma", 
      "T-cell lymphoma", 
      "lymphoma/leukemia", 
      "T-cell malignancies", 
      "World Health Organization", 
      "precursor T-cell lymphoblastic lymphoma/leukemia", 
      "T-cell lymphoblastic lymphoma/leukemia", 
      "allogeneic hematopoietic stem cell transplantation", 
      "adult T-cell lymphoma/leukemia", 
      "cutaneous T-cell lymphoma", 
      "hematopoietic stem cell transplantation", 
      "human T-cell lymphotropic virus", 
      "T-cell lymphoma/leukemia", 
      "lymphoblastic lymphoma/leukemia", 
      "monoclonal antibodies", 
      "first-line treatment", 
      "mature T-cell lymphomas", 
      "stem cell transplantation", 
      "B-cell lymphoma", 
      "mature T cells", 
      "anti-viral agents", 
      "histone deacetylase inhibitors", 
      "novel monoclonal antibody", 
      "natural killer", 
      "denileukin diftitox", 
      "cell transplantation", 
      "clinicopathologic profile", 
      "conventional chemotherapy", 
      "T cells", 
      "cell neoplasms", 
      "treatment protocol", 
      "lymphotropic virus", 
      "rare disease", 
      "prolymphocytic leukemia", 
      "deacetylase inhibitors", 
      "lymphoma", 
      "Health Organization", 
      "leukemia", 
      "malignancy", 
      "therapy", 
      "disease", 
      "further investigation", 
      "antibodies", 
      "treatment", 
      "unique association", 
      "significant improvement", 
      "alemtuzumab", 
      "diftitox", 
      "chemotherapy", 
      "prognosis", 
      "transplantation", 
      "neoplasms", 
      "outcomes", 
      "virus", 
      "killer", 
      "inhibitors", 
      "association", 
      "role", 
      "agents", 
      "protocol", 
      "improvement", 
      "profile", 
      "use", 
      "combination", 
      "number", 
      "investigation", 
      "organization"
    ], 
    "name": "Targeted therapies in T-cell malignancies", 
    "pagination": "39-47", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1040146758"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11523-006-0035-0"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11523-006-0035-0", 
      "https://app.dimensions.ai/details/publication/pub.1040146758"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_422.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11523-006-0035-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11523-006-0035-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11523-006-0035-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11523-006-0035-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11523-006-0035-0'


 

This table displays all metadata directly associated to this object as RDF triples.

169 TRIPLES      21 PREDICATES      100 URIs      83 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11523-006-0035-0 schema:about anzsrc-for:11
2 anzsrc-for:1107
3 anzsrc-for:1112
4 schema:author N2ed5893e60804d9ebe493343c3662b8c
5 schema:citation sg:pub.10.1007/s11912-002-0038-7
6 sg:pub.10.1038/332323a0
7 sg:pub.10.1038/nbt0698-535
8 sg:pub.10.1038/sj.bmt.1702867
9 sg:pub.10.1038/sj.leu.2403955
10 sg:pub.10.1038/sj.leu.2404306
11 sg:pub.10.1038/sj.thj.6200195
12 sg:pub.10.1385/mo:22:2:191
13 schema:datePublished 2006-11-22
14 schema:datePublishedReg 2006-11-22
15 schema:description The World Health Organization (WHO) has classified T-cell malignancies into mature T-cell and natural killer (NK)-cell neoplasms and precursor T-cell lymphoblastic lymphoma/leukemia. Mature T-cell lymphomas, alternatively known as peripheral T-cell lymphomas (PTCLs), are rare diseases with extremely heterogeneous clinicopathologic profiles. Treatment protocols for PTCL are mostly adapted from those used for B-cell lymphomas, but the prognosis is generally worse. More recently, monoclonal antibodies, including alemtuzumab (Campath-1H, anti-CD52) and denileukin diftitox (Ontak, anti-CD25), have been shown to be effective in the treatment of T-prolymphocytic leukemia (T-PLL) and cutaneous T-cell lymphoma. The unique association of human T-cell lymphotropic virus in adult T-cell lymphoma/leukemia has also led to the use of anti-viral agents in this disease with significant improvement in outcome. A number of novel monoclonal antibodies and histone deacetylase inhibitors are also being evaluated. The roles of these targeted therapies as first-line treatment or in combination with conventional chemotherapy and the roles of autologous and allogeneic hematopoietic stem cell transplantation in PTCL need further investigation.
16 schema:genre article
17 schema:isAccessibleForFree false
18 schema:isPartOf N3d66dc574dcb4031ba7b0621d7aaf005
19 N428e90d07de24802a8fe33c3fd00333d
20 sg:journal.1036678
21 schema:keywords B-cell lymphoma
22 Health Organization
23 T cells
24 T-cell lymphoblastic lymphoma/leukemia
25 T-cell lymphoma
26 T-cell lymphoma/leukemia
27 T-cell malignancies
28 World Health Organization
29 adult T-cell lymphoma/leukemia
30 agents
31 alemtuzumab
32 allogeneic hematopoietic stem cell transplantation
33 anti-viral agents
34 antibodies
35 association
36 cell neoplasms
37 cell transplantation
38 chemotherapy
39 clinicopathologic profile
40 combination
41 conventional chemotherapy
42 cutaneous T-cell lymphoma
43 deacetylase inhibitors
44 denileukin diftitox
45 diftitox
46 disease
47 first-line treatment
48 further investigation
49 hematopoietic stem cell transplantation
50 histone deacetylase inhibitors
51 human T-cell lymphotropic virus
52 improvement
53 inhibitors
54 investigation
55 killer
56 leukemia
57 lymphoblastic lymphoma/leukemia
58 lymphoma
59 lymphoma/leukemia
60 lymphotropic virus
61 malignancy
62 mature T cells
63 mature T-cell lymphomas
64 monoclonal antibodies
65 natural killer
66 neoplasms
67 novel monoclonal antibody
68 number
69 organization
70 outcomes
71 peripheral T-cell lymphoma
72 precursor T-cell lymphoblastic lymphoma/leukemia
73 profile
74 prognosis
75 prolymphocytic leukemia
76 protocol
77 rare disease
78 role
79 significant improvement
80 stem cell transplantation
81 therapy
82 transplantation
83 treatment
84 treatment protocol
85 unique association
86 use
87 virus
88 schema:name Targeted therapies in T-cell malignancies
89 schema:pagination 39-47
90 schema:productId N68760f671466491d92f028b2e2a54e04
91 Na99ff54ea4ad4a9fa632f3ec7bb8a65b
92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040146758
93 https://doi.org/10.1007/s11523-006-0035-0
94 schema:sdDatePublished 2022-12-01T06:25
95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
96 schema:sdPublisher Nd8bdc8a39aa34225b8c6b95252f71e79
97 schema:url https://doi.org/10.1007/s11523-006-0035-0
98 sgo:license sg:explorer/license/
99 sgo:sdDataset articles
100 rdf:type schema:ScholarlyArticle
101 N2ed5893e60804d9ebe493343c3662b8c rdf:first sg:person.011121156664.42
102 rdf:rest Ne512fa0b81f045e19bdc7fb5eacc6c46
103 N3d66dc574dcb4031ba7b0621d7aaf005 schema:volumeNumber 2
104 rdf:type schema:PublicationVolume
105 N428e90d07de24802a8fe33c3fd00333d schema:issueNumber 1
106 rdf:type schema:PublicationIssue
107 N68760f671466491d92f028b2e2a54e04 schema:name dimensions_id
108 schema:value pub.1040146758
109 rdf:type schema:PropertyValue
110 Na99ff54ea4ad4a9fa632f3ec7bb8a65b schema:name doi
111 schema:value 10.1007/s11523-006-0035-0
112 rdf:type schema:PropertyValue
113 Nd8bdc8a39aa34225b8c6b95252f71e79 schema:name Springer Nature - SN SciGraph project
114 rdf:type schema:Organization
115 Ne512fa0b81f045e19bdc7fb5eacc6c46 rdf:first sg:person.07707430152.30
116 rdf:rest rdf:nil
117 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
118 schema:name Medical and Health Sciences
119 rdf:type schema:DefinedTerm
120 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
121 schema:name Immunology
122 rdf:type schema:DefinedTerm
123 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
124 schema:name Oncology and Carcinogenesis
125 rdf:type schema:DefinedTerm
126 sg:journal.1036678 schema:issn 1776-2596
127 1776-260X
128 schema:name Targeted Oncology
129 schema:publisher Springer Nature
130 rdf:type schema:Periodical
131 sg:person.011121156664.42 schema:affiliation grid-institutes:grid.194645.b
132 schema:familyName Leung
133 schema:givenName Anskar Y. H.
134 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011121156664.42
135 rdf:type schema:Person
136 sg:person.07707430152.30 schema:affiliation grid-institutes:grid.194645.b
137 schema:familyName Liang
138 schema:givenName Raymond
139 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07707430152.30
140 rdf:type schema:Person
141 sg:pub.10.1007/s11912-002-0038-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015532547
142 https://doi.org/10.1007/s11912-002-0038-7
143 rdf:type schema:CreativeWork
144 sg:pub.10.1038/332323a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016704652
145 https://doi.org/10.1038/332323a0
146 rdf:type schema:CreativeWork
147 sg:pub.10.1038/nbt0698-535 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003509924
148 https://doi.org/10.1038/nbt0698-535
149 rdf:type schema:CreativeWork
150 sg:pub.10.1038/sj.bmt.1702867 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020320997
151 https://doi.org/10.1038/sj.bmt.1702867
152 rdf:type schema:CreativeWork
153 sg:pub.10.1038/sj.leu.2403955 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010474068
154 https://doi.org/10.1038/sj.leu.2403955
155 rdf:type schema:CreativeWork
156 sg:pub.10.1038/sj.leu.2404306 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020476651
157 https://doi.org/10.1038/sj.leu.2404306
158 rdf:type schema:CreativeWork
159 sg:pub.10.1038/sj.thj.6200195 schema:sameAs https://app.dimensions.ai/details/publication/pub.1056649458
160 https://doi.org/10.1038/sj.thj.6200195
161 rdf:type schema:CreativeWork
162 sg:pub.10.1385/mo:22:2:191 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007072512
163 https://doi.org/10.1385/mo:22:2:191
164 rdf:type schema:CreativeWork
165 grid-institutes:grid.194645.b schema:alternateName Division of Hematology and Bone Marrow Transplantation, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, People’s Republic of China
166 Queen Mary Hospital, Department of Medicine, K417, K Block, University of Hong Kong, Pok Fu Lam Road, Hong Kong SAR, People’s Republic of China
167 schema:name Division of Hematology and Bone Marrow Transplantation, Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, People’s Republic of China
168 Queen Mary Hospital, Department of Medicine, K417, K Block, University of Hong Kong, Pok Fu Lam Road, Hong Kong SAR, People’s Republic of China
169 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...